<DOC>
	<DOCNO>NCT00702975</DOCNO>
	<brief_summary>A phase II study combination therapy carboplatin -gemcitabine plus bevacizumab beyond progression patient locally advance and/or metastatic non-small cell lung cancer ( NSCLC ) receive prior chemotherapy .</brief_summary>
	<brief_title>Study Combination Therapy Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer ( NSCLC ) Who Have Not Received Prior Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced stage NSCLC ( IIIB malignant pleural effusion stage IV exclude squamous cell histology , measurable evaluable disease . No prior systemic therapy advance NSCLC , prior therapy early stage disease one regimen acceptable complete least 6 month prior study entry . Palliative radiotherapy painful bony metastasis permit prior study entry complete prior initiation study treatment , residual sequela therapy bone marrow suppression . Life expectancy least 3 month . ECOG Performance status 01 ( see appendix 2 ) Age 18 high . Female patient reproductive potential must negative serum pregnancy test within 72 hour prior start study medication . All female patient childbearing potential , male patient , must agree use medically acceptable method contraception agree abstinent throughout treatment period 3 month discontinuation treatment Patients must normal organ marrow function Prior systemic treatment advance NSCLC . One prior regimen ( 4 cycle ) neoadjuvant adjuvant therapy early stage disease allow complete least 6 month prior study entry . Known brain metastasis ( case clinical sign symptom brain metastasis radiological evaluation mandatory ) . Prior treatment bevacizumab erlotinib . History allergic reaction sensitivity attribute compound similar chemical biologic composition bevacizumab erlotinib . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Concomitant chemotherapy , radiotherapy investigational agent . Evidence bleed diathesis coagulopathy . Use full dose anticoagulant agent . Pregnant ( positive pregnancy test ) lactate woman . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start , anticipation need major surgical procedure course study . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior start . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior start . Serious , nonhealing wound , ulcer , bone fracture . Lung carcinoma squamous cell histology histology close proximity major vessel , significant cavitation assess treat investigator consultation attend radiologist . History hemoptysis ( bright red blood 2.5 ml ) . Significant comorbidities include : No uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Patients diagnose tracheaoesophageal fistula Another active malignancy except nonmelanoma skin cancer last 5 year . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>phase II</keyword>
	<keyword>NSCLC</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>erlotinib</keyword>
	<keyword>metastatic NSCLC</keyword>
</DOC>